ModernMedicine Resource Center More Topics
 

Biologic treatments for moderate-to-severe atopic dermatitis

Recruitment underway for atopic dermatitis serlopitant trialEarly trial results show a significant reduction of itch with the oral NK-1 antagonist serlopitant
When other treatments fail in atopic dermatitis, dupilumab succeedsDupilumab plus topical corticosteroids safe and effective after failure of cyclosporine in moderate-to-severe atopic dermatitis
The factors that drive atopic dermatitisThere are two pathways that lead to atopic dermatitis. Their origins differ, but they both impair the immune system and skin barrier in AD.
Relief from the itch in atopic dermatitisAn experimental drug designed to control itching in people with moderate-to-severe AD shows promise in early trial.
Gene mutation identified in atopic dermatitisA new study shows that mutations in the gene CARD11 are associated with severe atopic disease.
House dust mites and severe atopic dermatitis: A new connectionPatients with severe atopic dermatitis who have lower serum vitamin D levels have a high sensitivity to house dust mites which can aggravate their condition, a new study shows.
IL-31 pathway may lead to new treatments for pruritusIn early research, subcutaneous nemolizumab significantly reduced pruritus in moderate-to-severe atopic dermatitis adult patients.
Dupilumab maintains long-term benefits in atopic dermatitis
Dupilumab maintains long-term benefits in atopic dermatitisLong-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.
Center’s goal: Give skin disease researchers all they needA new research center makes a database of five million human pathology specimens and 22,000 living consented patients, all searchable by diagnoses, as well as cutting edge human analytic techniques available to anyone interested in carrying out translational skin disease research on human cells and tissues.
Phase 3 results demonstrate dupilumab efficacyNew data suggests positive safety and efficacy profile. Further studies need to assess long-term use.